iconLatest White Paper


  • Dr Reddy
  • |
  • 2025
  • |
  • 05/05/2025

Product Alert – Mavacamten

Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation... [More]

Structure
partical
icon

Year 2025

    • Dr Reddy
    • |
    • 2025
    • |
    • 05/05/2025

    Product Alert - Mavacamten

    Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation... [More]

    • Dr Reddy
    • |
    • 2025
    • |
    • 05/05/2025

    Product Alert - Mavacamten

    Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation... [More]

icon

Year 2024

    • Dr Reddy
    • |
    • 2024
    • |
    • 05/05/2025

    Product Alert - Mavacamten

    Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation... [More]

    • Dr Reddy
    • |
    • 2024
    • |
    • 05/05/2025

    Product Alert - Mavacamten

    Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation... [More]

    • Dr Reddy
    • |
    • 2024
    • |
    • 05/05/2025

    Product Alert - Mavacamten

    Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation... [More]

    • Dr Reddy
    • |
    • 2024
    • |
    • 05/05/2025

    Product Alert - Mavacamten

    Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation... [More]

    • Dr Reddy
    • |
    • 2024
    • |
    • 05/05/2025

    Product Alert - Mavacamten

    Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation... [More]

    • Dr Reddy
    • |
    • 2024
    • |
    • 05/05/2025

    Product Alert - Mavacamten

    • Planning USDMF by January 2025
    • Offers crystalline Form-1
    • Non-GMP API and COA are available
    [More]
icon

Year 2023

    • Dr Reddy
    • |
    • 2023
    • |
    • 05/05/2025

    Product Alert - Mavacamten

    Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation... [More]

    • Dr Reddy
    • |
    • 2023
    • |
    • 05/05/2025

    Product Alert - Mavacamten

    Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation... [More]

    • Dr Reddy
    • |
    • 2023
    • |
    • 05/05/2025

    Product Alert - Mavacamten

    Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation... [More]

    • Dr Reddy
    • |
    • 2023
    • |
    • 05/05/2025

    Product Alert - Mavacamten

    Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation... [More]

    • Dr Reddy
    • |
    • 2023
    • |
    • 05/05/2025

    Product Alert - Mavacamten

    Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation... [More]

    • Dr Reddy
    • |
    • 2023
    • |
    • 05/05/2025

    Product Alert - Mavacamten

    Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation... [More]


Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.